Diabetes with Chronic Kidney Disease

It's essential to test diabetic individuals with CKD with diabetes tests that also monitor chronic kidney disease? Ulta Lab Test offers special labs to monitor diabetes with chronic kidney disease.

SEE BELOW THE LIST OF TESTS FOR MORE INFORMATION ABOUT – Diabetes With Chronic Kidney Disease Blood Lab Tests


Name Matches
Apolipoprotein A1 (APO A1) has been reported to be a better predictor than HDL cholesterol and triglycerides for Coronary Artery Disease (CAD). Low levels of APO A1 in serum are associated with increased risk of CAD. The measurement of APO A1 may be of value in identifying patients with atherosclerosis. Apolipoprotein B (APO B) has been reported to be a more powerful indicator of CAD than total cholesterol or LDL cholesterol in angiographic CAD and in survivors of myocardial infarction. In some patients with CAD, APO B is elevated even in the presence of normal LDL cholesterol.

Increased CRP levels are found in inflammatory conditions including: bacterial infection, rheumatic fever, active arthritis, myocardial infarction, malignancies and in the post-operative state. This test cannot detect the relatively small elevations of CRP that are associated with increased cardiovascular risk.

Cardio IQ® Diabetes and ASCVD Risk Panel with Scores - Includes:  Cardio IQ® Glucose; Cardio IQ® Hemoglobin A1c; Cardio IQ® Cholesterol, Total; Cardio IQ® HDL Cholesterol; Cardio IQ® Triglycerides; Cardio IQ® Non-HDL and Calculated Components; Cardio IQ® Risks and Personal Factors

If Triglyceride is >400 mg/dL, Cardio IQ® Direct LDL will be performed at an additional charge (CPT code(s): 83721).

Clinical Significance

The increasing prevalence of obesity has led to an epidemic of diabetes mellitus and related complications, including ASCVD. Prediction of the risk of ASCVD and of developing diabetes in the Cardio IQ® lab report will simplify and improve the communication of those risks to patients.

This panel provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

  • Age: Years 
  • Gender: M (for male) or F (for female) 
  • Height Feet: Feet 
  • Height Inches: Inches 
  • Weight: lbs 
  • Race-African American: Y (for yes) or N (for no) 
  • Systolic Blood Pressure: mmHg
  • Diastolic Blood Pressure: mmHg
  • Treatment for High B.P.: Y (for yes) or N (for no) 
  • Diabetes Status: Y (for yes) or N (for no)
  • Parental History of Diab: Y (for yes) or N (for no) 
  • Smoking Status: Y (for Yes) or N (for no)

Cardio IQ® Diabetes Risk Panel with Score - 

Includes
Cardio IQ® Glucose; Cardio IQ® Hemoglobin A1c; Cardio IQ® Cholesterol, Total; Cardio IQ® HDL Cholesterol; Cardio IQ® Triglycerides; Cardio IQ® Non-HDL and Calculated Components; Cardio IQ® 8 Year Diabetes Risk

If Triglyceride is >400 mg/dL, Cardio IQ® Direct LDL will be performed at an additional charge (CPT code(s): 83721).

Clinical Significance

Permit the assessment of serum glucose levels and lipid levels and the prediction of the 8-year future risk of developing diabetes mellitus in patients without diabetes mellitus.

• Assess risk for developing type 2 diabetes mellitus
• Identify lifestyle interventions and/or pharmacotherapy
• This test provides an 8-year risk of developing type 2 diabetes

Type 1 diabetes mellitus is defined as a deficiency of insulin secretion. Type 2 diabetes, which accounts for greater than 90% of all diabetes cases, is caused by a combination of insulin resistance and an inadequate compensatory insulin secretion.

Type 2 diabetes frequently goes undiagnosed, because it has no classic symptoms of diabetes and it progresses slowly from a pre-diabetic state. 

The U.S. Centers for Disease Control and Prevention estimates that 37% of individuals that are greater than 20 years old and approximately  half of those are greater than 65 years old have pre-diabetes. These individuals are at high risk for progression to type 2 diabetes and are candidates for preventive therapy that include lifestyle modification, such as weight  loss, increased physical activity, and medication.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

  • Age: Years 
  • Gender: M (for male) or F (for female) 
  • Height Feet: Feet 
  • Height Inches: Inches 
  • Weight: lbs 
  • Race-African American: Y (for yes) or N (for no) 
  • Systolic Blood Pressure: mmHg
  • Diastolic Blood Pressure: mmHg
  • Treatment for High B.P.: Y (for yes) or N (for no) 
  • Diabetes Status: Y (for yes) or N (for no)
  • Parental History of Diab: Y (for yes) or N (for no) 
  • Smoking Status: Y (for Yes) or N (for no)

Catecholamines, Fractionated and VMA, 24-Hour Urine without Creatinine

Catecholamines are a group of similar substances released into the blood in response to physical or emotional stress. The primary catecholamines are dopamine, epinephrine (adrenaline), and norepinephrine. Catecholamine testing measures the amounts of these hormones in the urine and/or blood. Urine testing is recommended over blood testing.

Patient Preparation

It is preferable for the patient to be off medications for three days prior to collection. However, common antihypertensives (diuretics, ACE inhibitors, calcium channel blockers, alpha and beta blockers) may cause minimal or no interference.
Patient should avoid tobacco, tea, coffee, and strenuous exercise for 8-12 hours prior to collection.



A Complete Blood Count (CBC) Panel is used as a screening test for various disease states including anemia, leukemia and inflammatory processes.

A CBC blood test includes the following biomarkers: WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet count, Neutrophils, Lymphs, Monocytes, Eos, Basos, Neutrophils (Absolute), Lymphs (Absolute), Monocytes(Absolute), Eos (Absolute), Basos (Absolute), Immature Granulocytes, Immature Grans (Abs)


See individual tests

Most Popular

To screen for and monitor kidney dysfunction in those with known or suspected kidney disease. Cystatin C is a relatively small protein that is produced throughout the body by all cells that contain a nucleus and is found in a variety of body fluids, including the blood. It is produced, filtered from the blood by the kidneys, and broken down at a constant rate. This test measures the amount of cystatin C in blood to help evaluate kidney function.Cystatin C is filtered out of the blood by the glomeruli, clusters of tiny blood vessels in the kidneys that allow water, dissolved substances, and wastes to pass through their walls while retaining blood cells and larger proteins. What passes through the walls of the glomeruli forms a filtrate fluid. From this fluid, the kidneys reabsorb cystatin C, glucose, and other substances. The remaining fluid and wastes are carried to the bladder and excreted as urine. The reabsorbed cystatin C is then broken down and is not returned to the blood.


Diabetes Risk Panel with Score

• Assess risk for developing type 2 diabetes mellitus
• Identify lifestyle interventions and/or pharmacotherapy
• This test provides an 8-year risk of developing type 2 diabetes
Type 1 diabetes mellitus is defined as a deficiency of insulin secretion. Type 2 diabetes, which accounts for greater than 90% of all diabetes cases, is caused by a combination of insulin resistance and an inadequate compensatory insulin secretion.

Type 2 diabetes frequently goes undiagnosed, because it has no classic symptoms of diabetes and it progresses slowly from a pre-diabetic state. 
The U.S. Centers for Disease Control and Prevention estimates that 37% of individuals that are greater than 20 years old and approximately  half of those are greater than 65 years old have pre-diabetes. These individuals are at high risk for progression to type 2 diabetes and are candidates for preventive therapy that include lifestyle modification, such as weight  loss, increased physical activity, and medication.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

  • Age: Years 
  • Gender: M (for male) or F (for female) 
  • Height Feet: Feet 
  • Height Inches: Inches 
  • Weight: lbs 
  • Race-African American: Y (for yes) or N (for no) 
  • Systolic Blood Pressure: mmHg
  • Diastolic Blood Pressure: mmHg
  • Treatment for High B.P.: Y (for yes) or N (for no) 
  • Diabetes Status: Y (for yes) or N (for no)
  • Parental History of Diab: Y (for yes) or N (for no) 
  • Smoking Status: Y (for Yes) or N (for no)

 






This panel is designed for individuals diagnosed as having diabetes mellitus whose kidney disease has advanced to Stage 3/4 impairment. The panel affords the opportunity to assess electrolytes, phosphorus, serum creatinine/eGFR, hemoglobin, microalbumin, parathyroid hormone, calcium, and vitamin D. The grouping of these tests, readily identifiable as elements that adhere to guideline recommendations, is intended to facilitate the ready adherence to professional society clinical practice guidelines. Components of the testing related to the Management of CKD in diabetes, as outlined in the Standards of Medical Care in Diabetes 2013. These recommendations are in broad agreement with those published by the National Kidney Foundation and the American Association of Clinical Endocrinologists.

Most Popular

Useful in the diagnosis of hypochromic, microcytic anemias. Decreased in iron deficiency anemia and increased in iron overload.


Clinical Significance

The glucagon assay is useful primarily when considering a glucagon-secreting tumor of the pancreas. Glucagonomas cause an unusual but characteristic syndrome consisting of a rash, mild diabetes, weight loss and hypoamninoacidemia. Measurement of plasma glucagon confirms the diagnosis; glucagon levels are very high in the setting of glucagonoma.


Most Popular
Measures 1,5 anhydroglucitol, a glucose derived carbohydrate whose urinary excretion varies inversely with mean blood glucose. 1,5 anhydroglucitol appears to integrate variation in mean blood glucose over a period of about two weeks.

A Hemoglobin (Hb) A1c Blood Test evaluates the average amount of glucose in the blood. The A1c test will help determine whether you are at a higher risk of developing diabetes; to help diagnose diabetes and prediabetes; to monitor diabetes and to aid in treatment decisions.

To assist with control of blood glucose levels, the American Diabetes Association (ADA) has recommended glycated hemoglobin testing (HbA1c) twice a year for patients with stable glycemia, and quarterly for patients with poor glucose control. Interpretative ranges are based on ADA guidelines.


Most Popular
For diagnosis and monitoring of diabetes and insulin-secreting tumors.

A lipid panel includes:Total cholesterol —this test measures all of the cholesterol in all the lipoprotein particles.High-density lipoprotein cholesterol (HDL-C) — measures the cholesterol in HDL particles; often called "good cholesterol" because it removes excess cholesterol and carries it to the liver for removal.Low-density lipoprotein cholesterol (LDL-C) — calculates the cholesterol in LDL particles; often called "bad cholesterol" because it deposits excess cholesterol in walls of blood vessels, which can contribute to atherosclerosis. Usually, the amount of LDL cholesterol (LDL-C) is calculated using the results of total cholesterol, HDL-C, and triglycerides.Triglycerides — measures all the triglycerides in all the lipoprotein particles; most is in the very low-density lipoproteins (VLDL).Very low-density lipoprotein cholesterol (VLDL-C) — calculated from triglycerides/5; this formula is based on the typical composition of VLDL particles.Non-HDL-C — calculated from total cholesterol minus HDL-C.Cholesterol/HDL ratio — calculated ratio of total cholesterol to HDL-C.


Lyme disease is caused by a bacterium borrelia burgdorferi and is transmitted by ticks. EIA is the screening test with high sensitivity for antibody detection. Immunoblot testing qualitatively examines with high specificity antibodies in a patient's specimen. Immunoblot testing is appropriate for confirming a detected EIA test result.

Reflex
If Lyme Disease Antibody Screen is ≥0.90, then Lyme Disease Antibodies (IgG, IgM), Immunoblot will be performed at an additional charge of $63.00


Diabetic nephropathy is a complication of diabetes and is characterized by proteinuria. Before overt proteinuria develops, albumin excretion increases in those diabetic patients who are destined to develop diabetic nephropathy. There is a need to identify small, but abnormal, increases in the excretion of urinary albumin (in the range of 30-300 mg/day, ie, microalbuminuria). The National Kidney Foundation guidelines for the management of patients with diabetes and microalbuminuria recommend that all type 1 diabetic patients older than 12 years and all type 2 diabetic patients younger than 70 years have their urine tested for microalbuminuria yearly when they are under stable glucose control.


The assay is useful in making the diagnosis of primary hyperparathyroidism, secondary hyperparathyroidism, and a differential diagnosis of hypercalcemia. The assay helps in distinguishing hypercalcemia cause by either primary hyperparathyroidism or malignant disease.


Diabetes is the leading cause of kidney failure. More than 247,000 people are currently living with kidney failure that resulted from diabetes.

Diabetes is categorized by high levels of sugar in the blood. One of the long-term side effects of these changes in the cardiovascular system is the destruction of small blood vessels throughout the body. Unfortunately, this leads to kidney damage which can lead to chronic kidney disease and kidney failure.

Diabetes with chronic kidney disease is nothing small. Patients with both conditions have to have a physician monitor them regularly. If you're a diabetic who isn't getting regular testing, you could have kidney problems and not know.

To learn more, keep reading.

What Is Diabetes With Chronic Kidney Disease?

As stated before, diabetes with chronic kidney disease (also known as diabetic nephropathy) is the manifestation of chronic kidney disease that stems from diabetes. It should be noted that you can develop chronic kidney disease whether you have controlled or uncontrolled diabetes.

The damage to your small blood vessels can still happen even if you're within optimal ranges. However, keeping your diabetes controlled can reduce your risk of developing chronic kidney disease.

Risk Factors for Diabetes With Chronic Kidney Disease

The number one risk factor for chronic kidney disease is having diabetes, either type one or type two. With this, there are a few other risk factors to consider:

  • High blood sugar that is not controlled
  • High blood pressure that is not controlled
  • Smoking
  • High cholesterol

Lastly, patients with a family history of diabetes with chronic kidney disease are more likely to develop the conditions themselves.

Causes of Diabetes With Chronic Kidney Disease

As mentioned earlier, diabetes could cause damage to the blood vessels that cluster in your kidneys. These blood vessels are responsible for filtering all of the waste from the blood in your body. Therefore, if these blood vessels become damaged, this can lead to decreased kidney function and even kidney failure.

Chronic kidney disease is a common complication of both type one and type two diabetes.

Poorly controlled diabetes is more likely to lead to this complication than well-controlled diabetes. However, anyone with diabetes could develop the condition.

Too much sugar in the blood could cause kidney damage and lead to high blood pressure. This leads to even more complications as high blood pressure can lead to more kidney damage. This cycle happens repeatedly as high blood pressure leads to kidney damage which leads to high blood pressure.

What Are the Signs and Symptoms of Diabetes With Chronic Kidney Disease?

The early stages of diabetic nephropathy don't come with any signs or symptoms. You could be developing chronic kidney disease and not know it until you're in the latter stages of development. This is why it's so important to get kidney lab tests done regularly, especially if you have diabetes.

If the kidney disease does develop into later stages, some signs and symptoms may begin manifesting:

  • Hypertension (high blood pressure)
  • Proteinuria (protein in the urine)
  • Lower extremity edema (swelling in the legs, ankles, and feet)
  • Swelling in the eys
  • Increased frequency of urination
  • Reduced need for insulin or other diabetic medication
  • Confusion
  • Difficulty concentrating
  • Shortness of breath
  • Nausea
  • Vomiting
  • Loss of appetite
  • Fatigue
  • Persistent itchy skin

If you have diabetes and you're experiencing any of these symptoms, you should make an appointment with your primary care physician or your endocrinologist. Either healthcare provider can examine your symptoms and interpret your test results.

How Is Diabetes With Chronic Kidney Disease Diagnosed?

To diagnose diabetic nephropathy, healthcare providers have to gather plenty of information.

First, they're going to ask questions about your personal and family history. They're going to ask about your habits and symptoms as well.

Then, they're going to order blood and urine tests to examine how controlled or uncontrolled your diabetes is. These tests can also help them examine your kidney health.

In addition to these tests, your healthcare provider may order a CT scan or an MRI to look at your kidneys. Lastly, they may require a biopsy if your kidneys do appear compromised.

The Lab Tests to Screen, Diagnose, and Monitor Diabetes With Chronic Kidney Disease

If you're looking to get diabetes with chronic kidney disease tests, Ulta Lab Tests has a few different panels to choose from:

Our comprehensive panel tests for the most biomarkers. With this panel, you'll get the best look at your diabetes condition and kidney health.

Here are the biomarkers that our comprehensive panel looks for:

  • Apolipoprotein - a measure of proteins that bind to lipids in the blood
  • C-Reactive protein - a general marker of inflammation
  • CBC - a general panel that looks at red blood cells, white blood cells, and platelets
  • Comprehensive metabolic panel - a panel that looks at electrolytes in the blood
  • Cystatin C with eGFR - a protein controlled by kidneys
  • GlycoMark - a plasma test for monitoring glucose variability
  • Hemoglobin A1C - a measure of blood glucose over the past three months
  • Insulin - a measure of glucose-controlling hormone in the blood
  • Lipid panel with ratios - a measure of lipids (fats) in the blood
  • Microalbumin - a protein in the blood
  • Phosphate - a measure of phosphorous in the blood
  • PTH - parathyroid hormone
  • QuestAssure - a measure of vitamin D in the blood

Getting all of these labs will help you and your healthcare provider make better decisions about your health.

Get Your Diabetes Tests With Ulta Lab Tests

If you have diabetes, you need to check the health of your kidneys. Diabetes with chronic kidney disease can lead to life-altering complications.

That's why physicians recommend that patients with diabetes get regular kidney testing. Luckily, Ulta Lab Tests offers the diabetes tests that you need. We offer highly accurate and reliable tests so that you can make informed decisions about your health.

Here are some of the benefits that you get to experience if you order your tests from Ulta Lab Tests:

  • You'll get secure and confidential results
  • You don't need health insurance
  • You don't need a physician's referral
  • You'll get affordable pricing
  • We offer a 100% satisfaction guarantee 

Order your diabetes tests today, and you'll receive your results securely and confidentially online in 24 to 48 hours for most tests. With your results, you and your healthcare provider can take preventative measures against chronic kidney disease before it can develop.

Take control with Ulta Lab Tests today!